These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 3284672)

  • 1. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease.
    Fauser AA; Shustik C; Langleben A; Laurent G; Kanz L; Spurll GM; Price G; Ahlgren PD; Cooper BA
    Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
    Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
    Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
    Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease.
    Laurent G; Maraninchi D; Gluckman E; Vernant JP; Derocq JM; Gaspard MH; Rio B; Michalet M; Reiffers J; Dreyfus F
    Bone Marrow Transplant; 1989 Jul; 4(4):367-71. PubMed ID: 2789084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal T-cell colony formation in agar culture: an attractive assay to test the T-cell depletion from bone marrow.
    Farcet JP; Beaujean F; Cordonnier C; Pico J; Gourdin MF; Divine M; Bracq C; Bouguet J; Laurent G; Bernard A
    Exp Hematol; 1986 Dec; 14(11):1011-4. PubMed ID: 3536543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
    Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
    Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory control in predicting clinical efficacy of T cell-depletion procedures used for prevention of graft-versus-host disease: importance of limiting dilution analysis.
    Marciniak E; Romond EH; Thompson JS; Henslee PJ
    Bone Marrow Transplant; 1988 Nov; 3(6):589-98. PubMed ID: 3063328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
    Antin JH; Bierer BE; Smith BR; Guinan EC; Provost MM; Ferrara J; Macklis RM; Tarbell NJ; Blythman H; Bouloux C
    Prog Clin Biol Res; 1990; 333():207-15. PubMed ID: 1689852
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients.
    Sykes M; Chester CH; Sundt TM; Romick ML; Hoyles KA; Sachs DH
    J Immunol; 1989 Dec; 143(11):3503-11. PubMed ID: 2584703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
    Przepiorka D; LeMaistre CF; Huh YO; Luna M; Saria EA; Brown CT; Champlin RE
    Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cellular sorting methods in autologous (elimination of residual malignant cells) or allogeneic (T lymphocyte elimination) bone marrow grafts. Clinical pilot studies].
    Hervé P; Flesch M
    Nouv Rev Fr Hematol (1978); 1986; 28(2):97-105. PubMed ID: 2942838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for absence of toxicity of T101 immunotoxin on human hematopoietic progenitor cells prior to bone marrow transplantation.
    Douay L; Gorin NC; Lopez M; Casellas P; Liance MC; Jansen FK; Voisin GA; Baillou C; Laporte JP; Najman A
    Cancer Res; 1985 Jan; 45(1):438-41. PubMed ID: 3880666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconstitution of hematopoiesis after bone marrow purging with ricin A chain immunotoxin.
    Fauser AA; Kanz L; Casellas P; Laurent G; Cooper BA; Löhr GW
    Transplantation; 1986 Mar; 41(3):356-60. PubMed ID: 3485318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow transplantation in miniature swine. III. Graft-versus-host disease and the effect of T cell depletion of marrow.
    Sakamoto K; Sachs DH; Shimada S; Popitz-Bergez FA; Pennington LR; Pescovitz MD; McDonough MA; MacVittie TJ; Katz SI; Gress RE
    Transplantation; 1988 May; 45(5):869-75. PubMed ID: 3285532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic bone marrow transplantation: relation between chimaerism and immunity.
    Vossen J
    Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal T-lymphocyte colonies (CFU-TL) following bone marrow transplantation.
    Mitsuyasu RT; Li SN; Champlin RE; Gale RP
    Exp Hematol; 1986 Dec; 14(11):1049-55. PubMed ID: 3536545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.